Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry

The patient characteristics observed align with those observed in randomised controlled trials and other noninterventional studies. Patients on antifibrotic therapy generally had more severe disease profiles.

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2025-02-27
DOI
https://doi.org/10.1183/23120541.00926-2024
Citations
3
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
3.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry

Heinrike Wilkens, Markus Polke, Martin Schwaiblmair, Jürgen Behr et al.
3 citations
ERJ Open Research
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
3.04
article

Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry

Heinrike Wilkens, Markus Polke, Martin Schwaiblmair, Jürgen Behr, Stephan Eisenmann, Stephan Budweiser, Sven Glaeser, Beate Stubbe, Ralf Ewert, Hans‐Joachim Kabitz, Ioana Andreica, Christine Pausch, Benjamin Seeliger, Hubert Wirtz, David Pittrow, Antje Prasse, Tobias Veit, Lars Hagmeyer, Wolfgang Gesierich, Jens Klotsche, Peter Schramm, Ekaterina Krauss, Marion Frankenberger, Daniel Grund, Francesco Bonella, Werner von Wulffen, Achim Grünewaldt, Stephan Walterspacher, Michael Westhoff, J Kirschner, Edmund Koch, Bernd Seese, Dirk Koschel, Martin Claussen, Claus-Peter Kreutz, Matthias Held, Sabine Haberl, Karine Thabaret, Frank Reichenberger, Lea Drobbe, Julia Wälscher, Heike Biller, Dirk Skowasch, Philipp Markart, Andreas Güenther, Michael Kreuter, M. Weber, F. Joachim Meyer, Ulrich Neff, Claus Neurohr, Christian Grohé
article en
3 citations

Abstract

The patient characteristics observed align with those observed in randomised controlled trials and other noninterventional studies. Patients on antifibrotic therapy generally had more severe disease profiles.

ERJ Open ResearchVol. 11(3)
Goethe University Frankfurt (DE), Witten/Herdecke University (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), Universitätsmedizin Greifswald (DE), University Hospital Bonn (DE), University Hospital Augsburg (DE), München Klinik Bogenhausen (DE), Medizinische Hochschule Hannover (DE), Augenklinik Heidelberg (DE), Ruhrlandklinik (DE), Rheumazentrum Ruhrgebiet (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), German Rheumatism Research Centre (DE), Accadis Hochschule Bad Homburg (DE), Zentralklinik Bad Berka (DE), Vivantes Klinikum (DE), Clinica de Pneumologie Iaşi (RO), Asklepios Fachkliniken München-Gauting (DE), University Hospital Leipzig (DE), Krankenhaus Bethanien (DE), RoMed Kliniken (DE), German Center for Lung Research (DE), Klinikum Arnsberg (DE), Universities of Giessen and Marburg Lung Center (DE), University Hospital Frankfurt (DE), Lungenklinik Hemer (DE), GWT-TUD (Germany) (DE), Klinikum Konstanz (DE), LungenClinic Grosshansdorf (DE), Klinikum Würzburg Mitte (DE), University Hospital in Halle (DE), Klinikum Fulda (DE), University Hospital Carl Gustav Carus (DE), Technische Universität Dresden (DE), Charité - Universitätsmedizin Berlin (DE), Ludwig-Maximilians-Universität München (DE), University of Bamberg (DE)
Boehringer Ingelheim
Responsible consumption and production
Openalex Percentile: Top 9%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.